Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash from Operations (2022 - 2025)

Bioregenx (BRGX) has 4 years of Cash from Operations data on record, last reported at 71564.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 129.4% year-over-year to 71564.0; the TTM value through Sep 2025 reached 42025.0, up 92.47%, while the annual FY2024 figure was 324148.0, 78.6% up from the prior year.
  • Cash from Operations reached 71564.0 in Q3 2025 per BRGX's latest filing, down from 3205.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 37695.0 in Q1 2025 and bottomed at 649161.0 in Q2 2023.
  • Average Cash from Operations over 4 years is 128967.13, with a median of 33110.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: tumbled 5528.46% in 2023, then skyrocketed 136.16% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 4364.0 in 2022, then crashed by 5528.46% to 245626.0 in 2023, then skyrocketed by 95.37% to 11361.0 in 2024, then crashed by 529.91% to 71564.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 71564.0 in Q3 2025, 3205.0 in Q2 2025, and 37695.0 in Q1 2025.